ARCHIVES

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

This article is from The Cancer Letter archive.

Vol. 11 No. 42 | November 1, 1985

Download PDF Visit The Full Archive

Related Articles

House Members Form Group To Address Cancer Policy.

February 23, 2001

Brinker Again To Lead Komen As CEO

December 11, 2009

The Meeting At the Beverly Hills Suite: Salick, Zeneca Par Way Acrimoniously

May 2, 1997

Pfizer’s Withdrawal Of Mylotarg Signals Stronger FDA Resolve To Monitor Confirmatory Studies

June 25, 2010

In Brief: Bishop, Scein, Vaitkevicuis Named To NCAB; Hopkins Breaks Ground for Larger Center

October 7, 1994

Texts Of Workshop Report Summarized

November 8, 1996